Psychodermatology is a relatively new field in evolution and thus, there is a comparative paucity of information in general. However, when it comes to children and adolescents there is a complete vacuum of information as no other book has aimed to specifically address the psychodermatological issues facing this particular population. For assessment, diagnosis, comprehensive treatment of children with psychodermatologic conditions and establishing a relationship between skin and psyche, there is a lack of clear and relevant clinical information about these complex disorders. The complexity of these disorders is related to lack of understanding in genetic, embryonic, physiologic, neuroimmunologic, neurocutaneous, stress-related neuromodulation, and psychosomatic interconnections.
This book presents a clinically relevant approach to the management of psychodermatologic issues encountered in normal practice. Various classifications and major categories that are discussed include psychophysiologic disorders, psychiatric conditions with dermatologic manifestations, dermatologic disorders predisposing to psychiatric disorders, systemic diseases with psychodermatological manifestations, and special issues in management of psychocutaneous disorders in children and adolescents.
Inhaltsverzeichnis
1;Foreword I;23 2;Foreword II;27 3;Preface;29 4;Author index;37 5;Abbreviations;41 6;Part I: INTERFACE OF DERMATOLOGY AND PSYCHIATRY;47 6.1;1 Perspectives on management of pediatric dermatologie disorders;49 6.1.1;1.1 Introduction;49 6.1.2;1.2 Skin infections and infestations;49 6.1.2.1;1.2.1 Bacterial infections;49 6.1.2.2;1.2.2 Viral infections;61 6.1.3;1.3 HIV/AIDS;65 6.1.3.1;1.3.1 Non-infectious skin lesions;65 6.1.3.2;1.3.2 Bacterial infections in HIV;65 6.1.3.3;1.3.3 Viral infections in HIV;66 6.1.3.4;1.3.4 Fungal infections in HIV;66 6.1.3.5;1.3.5 Fungal infections;67 6.1.3.6;1.3.6 Topical antifungals;71 6.1.3.7;1.3.7 Infestations;72 6.1.4;1.4 Dermatitis;75 6.1.4.1;1.4.1 Irritant dermatitis;75 6.1.4.2;1.4.2 Dry-skin dermatitis;75 6.1.4.3;1.4.3 Seborrheic dermatitis;75 6.1.4.4;1.4.4 Allergic dermatitides;76 6.1.4.5;1.4.5 Idiopathic dermatitides;79 6.1.5;1.5 Hypersensitivity;79 6.1.5.1;1.5.1 Urticaria;79 6.1.5.2;1.5.2 Drug eruptions;81 6.1.6;1.6 Miscellaneous skin conditions;83 6.1.6.1;1.6.1 Acne vulgaris;83 6.1.6.2;1.6.2 Nevi;87 6.1.6.3;1.6.3 Papulosquamous disorders;90 6.1.6.4;1.6.4 Lichens;92 6.1.6.5;1.6.5 Psoriasis;95 6.1.7;1.7 Dermatologic manifestations of systematic disorders;98 6.1.7.1;1.7.1 Pruritus without rash;98 6.1.7.2;1.7.2 Inflammatory bowel disease (IBD);99 6.1.7.3;1.7.3 Erythema nodosum;99 6.1.7.4;1.7.4 Pyoderma gangrenosum;99 6.1.7.5;1.7.5 Less common skin manifestations;99 6.1.7.6;1.7.6 Management;99 6.1.8;1.8 Collagen vascular disease;100 6.1.8.1;1.8.1 Lupus erythematosus (SLE);100 6.1.8.2;1.8.2 Dermatomyositis;100 6.1.8.3;1.8.3 Juvenile idiopathic arthritis;100 6.1.8.4;1.8.4 Management;100 6.1.9;1.9 Endocrinologic disorders;101 6.1.9.1;1.9.1 Thyroid disorders;101 6.1.9.2;1.9.2 Diabetes mellitus;101 6.1.9.3;1.9.3 Adrenal disorders;101 6.1.9.4;1.9.4 Management;102 6.1.10;1.10 Hair and nails;102 6.1.10.1;1.10.1 Alopecia areata;102 6.1.10.2;1.10.2 Telogen effluvium;104 6.1.10.3;1.10.3 Androgenic alopecia;104 6.1.10.4;1.10.4 Trichotillomania;105
6.1.10.5;1.10.5 Traction alopecia;105 6.1.10.6;1.10.6 Hirsutism and hypertrichosis;105 6.1.10.7;1.10.7 Hair changes with systemic disease;106 6.1.10.8;1.10.8 Infection;106 6.1.10.9;1.10.9 Bacterial;108 6.1.10.10;1.10.10 Fungal;109 6.1.10.11;1.10.11 Onychodystrophy;110 6.1.10.12;1.10.12 Nail changes with systemic and nutritional disorders;111 6.2;2 Psychoneuroimmunology and other interactions between skin and psyche;115 6.2.1;2.1 Introduction;115 6.2.1.1;2.1.1 History of psychodermatology;116 6.2.1.2;2.1.2 Classification of psychodermatologic disorders;118 6.2.1.3;2.1.3 Psychological perspective of skin;118 6.2.1.4;2.1.4 Skin, mind, and the embryological embrace;120 6.2.2;2.2 Psychoneuroimmunology;121 6.2.2.1;2.2.1 Neuroendocrine response to stress;121 6.2.2.2;2.2.2 Immune response and central nervous system;122 6.2.2.3;2.2.3 Immune response and peripheral nervous system;123 6.2.2.4;2.2.4 Immune response and skin disease;123 6.2.2.5;2.2.5 Immune response and psychiatric disease;125 6.2.3;2.3 Conclusion;126 6.3;3 A clinicians approach to psychocutaneous diseases in adolescents: Untying the Gordian knot;129 6.3.1;3.1 Introduction;129 6.3.1.1;3.1.1 History taking skills in adolescent patients;129 6.3.2;3.2 Interviewing the adolescent patient;131 6.3.2.1;3.2.1 Confidentiality;133 6.3.2.2;3.2.2 Parental confidentiality;133 6.3.2.3;3.2.3 Health questionnaires;133 6.3.2.4;3.2.4 Interview techniques;134 6.3.2.5;3.2.5 Active listening skills;135 6.3.3;3.3 Concepts of the physical examination;136 6.3.4;3.4 Successful management of the adolescent patient;136 6.3.4.1;3.4.1 Informed consent;136 6.3.4.2;3.4.2 Shared decision makings;137 6.3.4.3;3.4.3 Improving compliance;138 6.3.5;3.5 Conclusion;138 6.4;4 Quality of life issues in children and adolescents with dermatological conditions and their wider impact on the family and society;141 6.4.1;4.1 Introduction;141 6.4.2;4.2 Pediatric quality of life and its assessment;142 6.4.3;4.3 Skin disease and quality of life;143 6.4.3.1;4.3
.1 Impact of skin diseases on childrens quality of life;143 6.4.3.2;4.3.2 Quality of life assessment in children with dermatological conditions;145 6.4.3.3;4.3.3 Childrens Dermatology Life Quality Index (CDLQI);146 6.4.3.4;4.3.4 Infants Dermatitis Quality of Life Index (IDQoL);146 6.4.3.5;4.3.5 Impact of skin disease on the quality of life of adolescents;147 6.4.4;4.4 Assessment of adolescents quality of life in dermatology;148 6.4.4.1;4.4.1 Teenagers QoL questionnaire (T-QoL);148 6.4.4.2;4.4.2 Skindex-Teen;149 6.4.4.3;4.4.3 Impact of skin disease on family quality of life: The greater patient concept;150 6.4.5;4.5 Assessment of family quality in dermatology;152 6.4.5.1;4.5.1 Family Dermatology Life Quality Index (FDLQI);152 6.4.5.2;4.5.2 Dermatitis Family Impact questionnaire (DFI);153 6.4.5.3;4.5.3 Parents Index of Quality of Life in Atopic Dermatitis (PIQoL-AD);154 6.4.5.4;4.5.4 Childhood Atopic Dermatitis Impact Scale (CADIS);154 6.4.5.5;4.5.5 Psoriasis Family Index (PFI);155 6.4.6;4.6 Societal impact of childhood dermatological conditions;155 6.4.7;4.7 Conclusions;156 7;Part II: PSYCHOPHYSIOLOGIC DISORDERS;163 7.1;5 Atopic dermatitis: a psychocutaneous review;165 7.1.1;5.1 Introduction;165 7.1.1.1;5.1.1 Epidemiology;165 7.1.2;5.2 Pathophysiologic factors in atopic dermatitis;166 7.1.2.1;5.2.1 Genetic predisposition;166 7.1.2.2;5.2.2 Socio-economic status;166 7.1.2.3;5.2.3 Family size;166 7.1.2.4;5.2.4 Food allergens;166 7.1.3;5.3 Psychoneuroimmunologic factors;167 7.1.3.1;5.3.1 Breast feeding;167 7.1.3.2;5.3.2 Environmental allergens;167 7.1.4;5.4 Psychophysiological aspects of atopic dermatitis;168 7.1.4.1;5.4.1 Impact of stress on the immunological system;168 7.1.4.2;5.4.2 Psychoanalytic hypothesis;169 7.1.4.3;5.4.3 Biopsychosocial model;170 7.1.4.4;5.4.4 Psychological dysregulation due to atopic dermatitis;170 7.1.5;5.5 Clinical features;171 7.1.6;5.6 Diagnosis;171 7.1.6.1;5.6.1 Allergy Testing;173 7.1.6.2;5.6.2 Differential Diagnosis;174 7.1.7;5.7 Managemen
t;174 7.1.7.1;5.7.1 Prevention of relapse;174 7.1.7.2;5.7.2 Food allergens;175 7.1.7.3;5.7.3 Aeroallergens;175 7.1.7.4;5.7.4 Optimizing the epidermal barrier (EB);175 7.1.7.5;5.7.5 Hydration therapy;176 7.1.7.6;5.7.6 Management of pruritus;176 7.1.7.7;5.7.7 Topical corticosteroids;177 7.1.7.8;5.7.8 Topical immunomodulators;180 7.1.8;5.8 Systematic treatment of atopic dermatits;180 7.1.8.1;5.8.1 Antihistamines;180 7.1.8.2;5.8.2 Phototherapy;181 7.1.8.3;5.8.3 Antibiotics;181 7.1.8.4;5.8.4 Systemic corticosteroids;182 7.1.8.5;5.8.5 Immunomodulators;182 7.1.8.6;5.8.6 Cyclosporine;183 7.1.8.7;5.8.7 Azathioprine;183 7.1.8.8;5.8.8 Infliximab;183 7.1.8.9;5.8.9 Interferon-.;184 7.1.8.10;5.8.10 Leukotriene inhibitors;184 7.1.9;5.9 Psychiatric comorbidities;184 7.1.9.1;5.9.1 Family dynamics;185 7.1.9.2;5.9.2 Internalizing and externalizing behaviors;185 7.1.9.3;5.9.3 Anxiety and depression;186 7.1.9.4;5.9.4 Personality traits;186 7.1.10;5.10 Management of psychiatric comorbidities;187 7.1.10.1;5.10.1 Multidisciplinary approach;187 7.1.10.2;5.10.2 Psychoeducation;187 7.1.10.3;5.10.3 Psychosocial assessment;187 7.1.10.4;5.10.4 Psychiatric symptoms review;188 7.1.10.5;5.10.5 Quality of life assessment;188 7.1.10.6;5.10.6 Psychodynamic therapy;188 7.1.10.7;5.10.7 Cognitive behavioral therapy;189 7.1.10.8;5.10.8 Behavioral modifications;189 7.1.10.9;5.10.9 Psychotropic medications;189 7.1.11;5.11 Conclusion;190 7.2;6 Psoriasis and children: A psychological approach;193 7.2.1;6.1 Introduction;193 7.2.1.1;6.1.1 Epidemiology;194 7.2.2;6.2 Dermatological clinical features;194 7.2.2.1;6.2.1 Plaque psoriasis;195 7.2.2.2;6.2.2 Guttate psoriasis;195 7.2.2.3;6.2.3 Erythrodermic psoriasis;195 7.2.2.4;6.2.4 Pustular psoriasis;196 7.2.2.5;6.2.5 Psoriatic arthritis;197 7.2.2.6;6.2.6 Inverse psoriasis;197 7.2.3;6.3 Psychological clinical features;198 7.2.3.1;6.3.1 Differential diagnosis;200 7.2.3.2;6.3.2 Psychotherapeutic intervention;201 7.2.3.3;6.3.3 Psychotherapy;202 7.2.4;6.4 Conclusions;205
7.3;7 The acnes: Acne vulgaris, acne rosacea, and acne excoriée;209 7.3.1;7.1 Acne Vulgaris;209 7.3.1.1;7.1.1 Introduction;209 7.3.1.2;7.1.2 Epidemiology;209 7.3.1.3;7.1.3 Pathogenesis;213 7.3.1.4;7.1.4 Classification;214 7.3.1.5;7.1.5 Management;214 7.3.1.6;7.1.6 Teratogenicity and isotretinoin;225 7.3.1.7;7.1.7 Depression, suicidality, and isotretinoin;226 7.3.2;7.2 Acne Rosacea;230 7.3.2.1;7.2.1 Pathophysiology;231 7.3.2.2;7.2.2 Management of acne rosacea;232 7.3.3;7.3 Acne Variants;233 7.3.4;7.4 Conclusion;233 7.4;8 Psychogenic purpura (Gardner-Diamond syndrome);239 7.4.1;8.1 Introduction;239 7.4.2;8.2 History;239 7.4.3;8.3 Etiology and pathogenesis;240 7.4.4;8.4 Clinical features;241 7.4.5;8.5 Differential diagnosis;241 7.4.5.1;8.5.1 Disease course;241 7.4.5.2;8.5.2 Histopathology;241 7.4.5.3;8.5.3 Laboratory testings;242 7.4.5.4;8.5.4 Psychological disturbances;242 7.4.6;8.6 Treatment approaches and recommendations;242 7.4.7;8.7 Conclusion;243 8;Part III: PSYCHIATRIC DISORDERS WITH DERMATOLOGIC MANIFESTATIONS;245 8.1;9 Body dysmorphic disorder in adolescents;247 8.1.1;9.1 Introduction;247 8.1.2;9.2 Definition;248 8.1.2.1;9.2.1 Epidemiology;249 8.1.2.2;9.2.2 Clinical features;249 8.1.2.3;9.2.3 Differential diagnosis;250 8.1.3;9.3 Management;251 8.1.3.1;9.3.1 Preliminary considerations;251 8.1.3.2;9.3.2 The clinical interview;252 8.1.3.3;9.3.3 Assessment;252 8.1.3.4;9.3.4 Patient education;254 8.1.3.5;9.3.5 Treatment;254 8.1.4;9.4 Other treatment techniques;256 8.1.4.1;9.4.1 Anxiety management training (AMT);256 8.1.4.2;9.4.2 Eye movement desensitization and reprocessing (EMDR);257 8.1.4.3;9.4.3 Family therapy;257 8.1.4.4;9.4.4 Group therapy;257 8.1.4.5;9.4.5 Metaphors;257 8.1.4.6;9.4.6 Mindfulness;258 8.1.4.7;9.4.7 Intervention;258 8.1.4.8;9.4.8 Nonpsychiatric medical treatment;258 8.1.4.9;9.4.9 Final management considerations;259 8.1.5;9.5 Conclusions;259 8.2;10 Delusional infestation in childhood, adolescence, and adulthood;263 8.2.1;10.1 Introduction;263 8.
2.2;10.2 How to diagnose a delusion;264 8.2.3;10.3 Primary and secondary delusional infestation;265 8.2.4;10.4 The context of children and adolescence;266 8.2.5;10.5 Clinical pictures;267 8.2.5.1;10.5.1 Case one;267 8.2.5.2;10.5.2 Case two;268 8.2.5.3;10.5.3 Case Three;269 8.2.5.4;10.5.4 Commentary on these three cases;270 8.2.6;10.6 Delusional elaboration (Wahnarbeit);270 8.2.7;10.7 Prevalence of delusional infestation;272 8.2.7.1;10.7.1 Treatment;273 8.2.7.2;10.7.2 Which antipsychotic in DI?;274 8.2.8;10.8 Antipsychotics;276 8.2.9;10.9 Conclusion;278 8.3;11 Dermatitis artefacta, skin picking, and other self-injurious behaviors: A psychological perspective;283 8.3.1;11.1 Introduction;283 8.3.2;11.2 Epidemiology;285 8.3.3;11.3 Etiology;287 8.3.4;11.4 Clinical features;289 8.3.4.1;11.4.1 Dermatitis Artefacta;291 8.3.4.2;11.4.2 Skin picking;292 8.3.4.3;11.4.3 Self-mutilation behavior;292 8.3.5;11.5 Differential diagnosis;294 8.3.6;11.6 Management;294 8.3.6.1;11.6.1 Pharmacological Treatment;297 8.3.6.2;11.6.2 Psychotherapy;297 8.3.6.3;11.6.3 Issues with Treatment;301 8.3.7;11.7 Conclusions;303 8.4;12 Trichotillomania;307 8.4.1;12.1 Introduction;307 8.4.2;12.2 Definition;307 8.4.3;12.3 Differential diagnosis;308 8.4.4;12.4 Assessment;310 8.4.5;12.5 Management;312 8.4.5.1;12.5.1 Psychotherapy;313 8.4.5.2;12.5.2 Medication;313 8.4.6;12.6 Conclusions: Future directions;314 8.5;13 Psychogenic pruritus with particular emphasis on children and adolescents;317 8.5.1;13.1 Introduction;317 8.5.2;13.2 Epidemiology;318 8.5.3;13.3 Clinical features;319 8.5.4;13.4 Differential diagnosis;320 8.5.5;13.5 Management;321 8.5.6;13.6 Conclusion;323 9;Part IV: DERMATOLOGIC DISORDERS PREDISPOSING TO PSYCHIATRIC DISORDERS;327 9.1;14 Disorders of hair loss;329 9.1.1;14.1 Introduction;329 9.1.2;14.2 Causes of hair loss;329 9.1.3;14.3 Diagnostic approach to hair loss;331 9.1.3.1;14.3.1 History;331 9.1.3.2;14.3.2 Examination;331 9.1.3.3;14.3.3 Laboratory investigation;332 9.1.4;14.4 Tinea capiti
s;332 9.1.5;14.5 Telogen effluvium;333 9.1.6;14.6 Alopecia areata;333 9.1.7;14.7 Male pattern hair loss;334 9.1.8;14.8 Hair Loss due to Chemotherapy;334 9.1.9;14.9 Psychiatric aspects;334 9.1.9.1;14.9.1 Psychological treatment approaches;336 9.1.10;14.10 Conclusion;337 9.2;15 Disorders of skin pigmentation;341 9.2.1;15.1 Introduction;341 9.2.2;15.2 Disorders of hypopigmentation;342 9.2.2.1;15.2.1 Vitiligo;342 9.2.2.2;15.2.2 Albinism;344 9.2.2.3;15.2.3 Postinflammatory hypopigmentation;344 9.2.2.4;15.2.4 Pityriasis alba;345 9.2.2.5;15.2.5 Tinea versicolor;345 9.2.3;15.3 Disorders of hyperpigmentation;346 9.2.3.1;15.3.1 Postinflammatory hyperpigmentation;346 9.2.3.2;15.3.2 Melasma;346 9.2.3.3;15.3.3 Hyperpigmentation associated with medical disorders;346 9.2.3.4;15.3.4 Café-au-lait spots;347 9.2.3.5;15.3.5 Lentigines;347 9.2.4;15.4 Psychological aspects of disorders of pigmentations;347 9.2.4.1;15.4.1 Psychosocial management of disorders of pigmentation;349 9.2.5;15.5 Conclusion;350 9.3;16 Skin adnexal disorders;353 9.3.1;16.1 Hidradenitis suppurativa (HS);353 9.3.1.1;16.1.1 Introduction;353 9.3.1.2;16.1.2 Diagnosis;353 9.3.1.3;16.1.3 Etiology;354 9.3.1.4;16.1.4 Clinical features;355 9.3.1.5;16.1.5 Differential Diagnosis;356 9.3.2;16.2 Hyperhidrosis;357 9.3.2.1;16.2.1 Definition;357 9.3.2.2;16.2.2 Epidemiology;358 9.3.2.3;16.2.3 Etiology;358 9.3.2.4;16.2.4 Clinical features;359 9.3.2.5;16.2.5 Differential diagnosis;359 9.3.2.6;16.2.6 Management;360 9.3.3;16.3 Anhidrotic ectodermal dysplasia;362 9.3.3.1;16.3.1 Definition;362 9.3.3.2;16.3.2 Epidemiology;362 9.3.3.3;16.3.3 Clinical features;362 9.3.3.4;16.3.4 Differential diagnosis;362 9.3.3.5;16.3.5 Management;363 9.3.4;16.4 Nevus sebaceous;363 9.3.4.1;16.4.1 Definition;363 9.3.4.2;16.4.2 Epidemiology;363 9.3.4.3;16.4.3 Clinical features;363 9.3.4.4;16.4.4 Differential diagnosis;364 9.3.4.5;16.4.5 Management;364 9.3.5;16.5 Conclusion;364 10;Part V: SYSTEMATIC DISEASES WITH PSYCHODERMATOLOGIC MANIFESTATIONS;367 10.1;17 N
eurocutaneous disorders;369 10.1.1;17.1 Introduction;369 10.1.2;17.2 Neurofibromatosis;369 10.1.2.1;17.2.1 Clinical features;371 10.1.2.2;17.2.2 Neuropsychiatric aspects of neurofibromatosis type 1;371 10.1.2.3;17.2.3 Management;372 10.1.2.4;17.2.4 NF1 summary;374 10.1.3;17.3 Tuberous Sclerosis Complex (TSC);374 10.1.3.1;17.3.1 Introduction;374 10.1.3.2;17.3.2 Clinical features of TSC;375 10.1.3.3;17.3.3 Neurologic lesions;375 10.1.3.4;17.3.4 Psychiatric symptoms;375 10.1.3.5;17.3.5 Management;376 10.1.3.6;17.3.6 Treatment of neuropsychiatric problems;376 10.1.4;17.4 Conclusion;378 10.2;18 Collagen vascular disorders: Psychiatric and dermatologic manifestations;381 10.2.1;18.1 Lupus erythematosus (LE);381 10.2.1.1;18.1.1 Epidemiology;381 10.2.1.2;18.1.2 Clinical features;381 10.2.1.3;18.1.3 Cutaneous manifestations;382 10.2.1.4;18.1.4 Neuropsychiatric systemic lupus erythematosus (NPSLE);383 10.2.1.5;18.1.5 Differential diagnosis;386 10.2.1.6;18.1.6 Clinical diagnosis;386 10.2.1.7;18.1.7 Diagnostic workup;388 10.2.1.8;18.1.8 Management;388 10.2.1.9;18.1.9 Treatment of cutaneous lupus lesions;389 10.2.1.10;18.1.10 Treatment of NPSLE;389 10.2.2;18.2 Dermatomyositis;390 10.2.2.1;18.2.1 Epidemiology;390 10.2.2.2;18.2.2 Clinical features;391 10.2.2.3;18.2.3 Cutaneous manifestations;391 10.2.2.4;18.2.4 Psychiatric manifestations;392 10.2.2.5;18.2.5 Management;393 10.2.3;18.3 Rheumatoid Arthritis;394 10.2.3.1;18.3.1 Epidemiology;394 10.2.3.2;18.3.2 Etiopathogenesis;395 10.2.3.3;18.3.3 Clinical features;395 10.2.3.4;18.3.4 Cutaneous manifestations;395 10.2.3.5;18.3.5 Psychiatric manifestations;397 10.2.3.6;18.3.6 Laboratory findings;399 10.2.3.7;18.3.7 Management;400 10.2.3.8;18.3.8 Management of psychiatric issues;402 10.3;19 Psychocutaneous manifestations of endocrine disorders;407 10.3.1;19.1 Introduction;407 10.3.2;19.2 Diabetes Mellitus;407 10.3.2.1;19.2.1 Clinical features;408 10.3.2.2;19.2.2 Dermatological manifestations;409 10.3.2.3;19.2.3 Psychiatric manifestations
;411 10.3.2.4;19.2.4 Management of psychiatric conditions;412 10.3.3;19.3 Disorders of growth hormone;413 10.3.3.1;19.3.1 Acromegaly;413 10.3.3.2;19.3.2 Dermatological manifestations;413 10.3.3.3;19.3.3 Psychiatric manifestations;414 10.3.3.4;19.3.4 Diagnostic workup;415 10.3.3.5;19.3.5 Clinical management;415 10.3.3.6;19.3.6 Management of dermatological manifestations;416 10.3.3.7;19.3.7 Management of psychiatric manifestations;416 10.3.4;19.4 Thyroid hormone disorders;416 10.3.4.1;19.4.1 Hypothyroidism;416 10.3.4.2;19.4.2 Hyperthyroidism;417 10.3.4.3;19.4.3 Clinical features of thyroid disorders;417 10.3.4.4;19.4.4 Dermatological manifestations of hypothyroidism;418 10.3.4.5;19.4.5 Dermatological manifestations of hyperthyroidism;419 10.3.4.6;19.4.6 Psychiatric manifestations;419 10.3.4.7;19.4.7 Diagnostic workup;421 10.3.4.8;19.4.8 Management of hypothyroidism;421 10.3.4.9;19.4.9 Management of hyperthyroidism;421 10.3.4.10;19.4.10 Management of psychiatric disorders;423 10.3.5;19.5 Adrenal gland disorders;424 10.3.5.1;19.5.1 Hypoadrenocorticism (adrenal insufficiency [AI] or Addison disease [AD]);424 10.3.5.2;19.5.2 Hyperadrenocorticism (Cushing syndrome);426 10.3.6;19.6 Disorders of parathyroid glands;430 10.3.6.1;19.6.1 Hypoparathyroidism;430 10.3.6.2;19.6.2 Hyperparathyroidism;434 10.3.7;19.7 Disorders of hormones of the reproductive system;436 10.3.8;19.8 Androgen disorders;436 10.3.8.1;19.8.1 Hypogonadism in males;436 10.3.8.2;19.8.2 Androgen disorders in Females;437 10.3.9;19.9 Estrogen disorders;440 10.3.9.1;19.9.1 Estrogen disorders in males;440 10.3.9.2;19.9.2 Estrogen disorders in females;440 10.3.9.3;19.9.3 Psychiatric manifestations of disorders of androgen and estrogens;441 10.3.10;19.10 Conclusion;442 10.4;20 Inborn errors of metabolism with psychiatric and dermatologic features;449 10.4.1;20.1 Introduction;449 10.4.2;20.2 Phenylketonuria [PKU];449 10.4.2.1;20.2.1 Genetics and pathophysiology;450 10.4.2.2;20.2.2 Clinical features;451 10.4.2.3;20.2.3
Cutaneous manifestations;452 10.4.2.4;20.2.4 Psychiatric manifestations;452 10.4.2.5;20.2.5 Laboratory diagnosis;453 10.4.2.6;20.2.6 Management;453 10.4.3;20.3 Hartnup disease;455 10.4.3.1;20.3.1 Genetics and pathophysiology;455 10.4.3.2;20.3.2 Cutaneous manifestations;455 10.4.3.3;20.3.3 Psychiatric manifestations;455 10.4.3.4;20.3.4 Laboratory findings;456 10.4.3.5;20.3.5 Management;456 10.4.4;20.4 Homocystinuria;456 10.4.4.1;20.4.1 Genetics and pathophysiology;456 10.4.4.2;20.4.2 Clinical features;456 10.4.4.3;20.4.3 Cutaneous manifestations;457 10.4.4.4;20.4.4 Psychiatric Manifestations;457 10.4.4.5;20.4.5 Management;458 10.4.5;20.5 Porphyrias;458 10.4.5.1;20.5.1 Genetics and prevalence;458 10.4.5.2;20.5.2 Clinical features;459 10.4.5.3;20.5.3 Cutaneous manifestations;459 10.4.5.4;20.5.4 Psychiatric manifestations;460 10.4.5.5;20.5.5 Laboratory diagnosis;461 10.4.5.6;20.5.6 Management;461 10.4.6;20.6 Conclusion;462 11;Part VI: SPECIAL ISSUES IN MANAGEMENT OF PSYCHOCUTANEOUS DISORDERS;467 11.1;21 Psychiatric complications of dermatological treatments;469 11.1.1;21.1 Introduction;469 11.1.2;21.2 Epidemiology;469 11.1.3;21.3 Clinical features by medication category;470 11.1.3.1;21.3.1 Antibacterial agents;470 11.1.3.2;21.3.2 Antiviral agents;471 11.1.3.3;21.3.3 Corticosteroids;472 11.1.3.4;21.3.4 Dapsone;472 11.1.3.5;21.3.5 Antimalarial agents;472 11.1.3.6;21.3.6 Retinoids;473 11.1.3.7;21.3.7 Interferons;474 11.1.3.8;21.3.8 Other agents;474 11.1.4;21.4 Differential diagnosis;474 11.1.5;21.5 Management;474 11.1.5.1;21.5.1 Drug-drug interactions;475 11.1.5.2;21.5.2 Non-pharmacologic interventions;475 11.1.6;21.6 Conclusion;476 11.2;22 Dermatologic manifestations of psychotropic medications;479 11.2.1;22.1 Introduction;479 11.2.1.1;22.1.1 Epidemiology;479 11.2.2;22.2 Diagnosis;480 11.2.3;22.3 Pathogenesis;481 11.2.4;22.4 Categories;482 11.2.5;22.5 Common adverse cutaneous reactions;482 11.2.5.1;22.5.1 Pruritus;482 11.2.5.2;22.5.2 Exanthematous eruptions;482 11.2.5.3;
22.5.3 Urticaria and angioedema;496 11.2.5.4;22.5.4 Fixed drug eruptions;497 11.2.5.5;22.5.5 Photosensitivity;497 11.2.5.6;22.5.6 Pigmentation;498 11.2.5.7;22.5.7 Diaphoresis;498 11.2.5.8;22.5.8 Alopecia;498 11.2.6;22.6 Serious and life-threatening cutaneous reactions;499 11.2.6.1;22.6.1 Erythema multiforme;499 11.2.6.2;22.6.2 Stevens-Johnson Syndrome and Toxic Epidermolysis Necrolysis;499 11.2.6.3;22.6.3 Drug hypersensitivity syndrome;500 11.2.6.4;22.6.4 Vasculitis;501 11.2.6.5;22.6.5 Exfoliative dermatitis;501 11.2.6.6;22.6.6 Anaphylactoid reactions;502 11.2.7;22.7 General dermatologic conditions;502 11.2.7.1;22.7.1 Acneiform eruptions;502 11.2.7.2;22.7.2 Psoriasiform eruption;503 11.2.7.3;22.7.3 Seborrheic eruption;503 11.2.7.4;22.7.4 Lichenoid eruption;503 11.2.8;22.8 Conclusion;504 11.3;23 Non-pharmacological approaches to treat psychocutaneous disorders;507 11.3.1;23.1 Introduction;507 11.3.2;23.2 Non-pharmacological modalities;508 11.3.2.1;23.2.1 Acupuncture;508 11.3.2.2;23.2.2 Aromatherapy;508 11.3.2.3;23.2.3 Biofeedback;509 11.3.2.4;23.2.4 Brief dynamic psychotherapy;510 11.3.2.5;23.2.5 Cognitive behavioral therapy methods;510 11.3.2.6;23.2.6 Emotional freedom techniques (EFT);510 11.3.2.7;23.2.7 Eye Movement Desensitizing and Reprocessing (EMDR);511 11.3.2.8;23.2.8 Hypnosis;511 11.3.2.9;23.2.9 Music;512 11.3.2.10;23.2.10 Placebo;513 11.3.2.11;23.2.11 Suggestion;513 11.3.3;23.3 Conclusion;513 11.4;24 Psychiatric disorders frequently encountered in dermatology practices;517 11.4.1;24.1 Introduction;517 11.4.1.1;24.1.1 Epidemiology;518 11.4.2;24.2 Mood disorders;518 11.4.2.1;24.2.1 Epidemiology;518 11.4.2.2;24.2.2 Diagnosis of depressive disorders;521 11.4.2.3;24.2.3 Differential diagnosis of depressive disorders;522 11.4.2.4;24.2.4 Management of depressive disorders;522 11.4.3;24.3 Bipolar spectrum disorders;523 11.4.3.1;24.3.1 Types of bipolar disorders;524 11.4.3.2;24.3.2 Diagnosis of bipolar disorders;526 11.4.3.3;24.3.3 Differential diagnosis of bipolar
disorders;527 11.4.4;24.4 Anxiety spectrum disorders;531 11.4.4.1;24.4.1 Obsessive compulsive disorder;532 11.4.4.2;24.4.2 Social anxiety disorder (SAD);534 11.4.4.3;24.4.3 Eating disorders;537 11.4.5;24.5 Personality disorders (PDs);540 11.4.5.1;24.5.1 Introduction;540 11.4.5.2;24.5.2 Clinical diagnosis;541 11.4.6;24.6 Conclusion;544 12;APPENDIX;547 12.1;25 About the editors;549 12.2;26 FDA approved psychotropic medication indications for children and adolescents;553 12.3;27 Common psychiatric terms;555 12.4;28 Common dermatotologic lesions;559 13;Index;565 14;Plate section;573